Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of HepBQuin New Process
NCT03899142Phase 1Completed
- Sponsor
- Prothya Biosolutions
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HepBQuin in hepatitis B (HBV), sponsored by Prothya Biosolutions. Primary endpoint: half-life of anti-HBs antibodies at 84 days. Started Mar 2019; status: completed.
02
Drugs
HepBQuin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03899142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899142.